Companies Favor Funding In The Front End As Repatriation Looms – ValueWalk Premium

Companies Favor Funding In The Front End As Repatriation Looms

Corporations like funding In the front, but first what the heck does that mean?

To fund the acquisition of Kite Pharma, Gilead Sciences priced a $3 billion bond deal and took out a $6 billion term loan. This in itself isn't that unusual. Companies have been making heavy use of low-interest rates to finance acquisitions through debt since the great financial crisis.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

0